Medicines in Clinical Practice
Medication incidents, uncertainty, escalation and applied professional judgement
Applied learning on medication incidents, uncertainty, escalation and applied professional judgement.
Learning objectives
• Respond to medication incidents and near misses with immediate patient safety as the first priority. • Distinguish individual error, system weakness and unavoidable uncertainty. • Escalate when the prescribing decision exceeds available information, competence or authority. • Use incident reporting and learning systems constructively. • Apply a structured judgement framework to complex prescribing scenarios.
Overview
Learning objectives
- Respond to medication incidents and near misses with immediate patient safety as the first priority.
- Distinguish individual error, system weakness and unavoidable uncertainty.
- Escalate when the prescribing decision exceeds available information, competence or authority.
- Use incident reporting and learning systems constructively.
- Apply a structured judgement framework to complex prescribing scenarios.
When something has gone wrong
The first task after a medication incident is to protect the patient: identify what was given or omitted, assess likely consequences, arrange examination, observations, investigations or treatment where needed, and seek urgent specialist advice when appropriate. Administrative reporting comes after immediate clinical risk has been addressed. A near miss also deserves attention because it may expose a system weakness before harm occurs.
Errors rarely have a single cause
Medicine incidents can involve prescribing, transcription, dispensing, administration, monitoring or communication. Contributing factors may include workload, interruptions, similar names, confusing interfaces, unclear responsibility, incomplete reconciliation, software design, stock or formulation changes, and assumptions made during handover. Focusing only on the last person in the chain can miss the conditions that made the error likely.
Duty of candour and openness
Where a patient has suffered harm, clinicians should follow professional and organisational requirements for openness and duty of candour. Explain what is known, what is being done to address the consequences, and what will happen next. Do not speculate beyond the available facts or alter records retrospectively. Correct factual documentation transparently according to local record standards.
Report to learn, not merely to count
NICE medicines-optimisation guidance emphasises systems for identifying, reporting and learning from medicines-related patient-safety incidents. Local reporting should capture enough context to support learning. Some events may also require regulatory reporting, such as a Yellow Card for a suspected adverse drug reaction or device incident. These reporting routes have different purposes and one does not automatically replace another.
Uncertainty is a clinical fact, not a failure
Complex prescribing often involves incomplete evidence, conflicting priorities and changing physiology. Safe practice is not the absence of uncertainty but recognising it, reducing it where possible and making the residual uncertainty explicit. If key information is unavailable, consider whether treatment can wait, whether a safer temporary option exists, whether monitoring can reduce risk, or whether senior, pharmacy, specialist or toxicology advice is needed.
Escalation thresholds
Escalate when the decision is outside your competence, when a medicine-specific risk is unfamiliar, when legal or governance requirements are unclear, when serious harm is possible, when the patient’s condition is unstable, or when different teams disagree about responsibility. Escalation should be purposeful: state the question, current risk, relevant facts and the decision required. Simply “asking someone senior” without transferring the essential information does not make the process safe.
Sources for this module
Professional judgement and defensibility
A defensible prescribing decision links evidence and guidance to the individual patient. It identifies the indication, alternatives, benefit-harm balance, patient preferences, key uncertainties, monitoring and review plan. Departing from guidance may be appropriate, but the reason should be clinically coherent and documented. Following a guideline mechanically is not a defence if the patient’s circumstances clearly require a different approach.
Final programme framework
Before completing a complex prescribing decision ask: Do I know enough about the patient? Is there a clear indication and goal? Are allergies, interactions, organ function and current medicines understood? Is the dose and route appropriate? What monitoring and follow-up are needed? What could go wrong and how would it be detected? Is responsibility clear across interfaces? Have I involved the patient? If uncertainty remains, have I escalated it appropriately and documented the reasoning?
Sources for this module
- NICE NG5 - Medicines optimisation: systems for identifying, reporting and learning from medicines-related patient safety incidents.
- GMC - Good medical practice and Good practice in proposing, prescribing, providing and managing medicines and devices.
- MHRA - Yellow Card scheme guidance.
- AWTTC - National Prescribing Indicators and Welsh medicines-safety resources.
- Local patient-safety incident, duty-of-candour and medicines-governance policies.
Educational note: medicine-specific doses, thresholds, contraindications and rapidly changing regulatory requirements must be checked against current authoritative guidance and local policy at the point of care.
